These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 30612850)

  • 1. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
    Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
    Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
    Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
    BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
    Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
    J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.
    Heidelbaugh JJ; Stelwagon M; Miller SA; Shea EP; Chey WD
    Am J Gastroenterol; 2015 Apr; 110(4):580-7. PubMed ID: 25781368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.
    Solem CT; Patel H; Mehta S; Mody R; Macahilig C; Gao X
    Curr Med Res Opin; 2016 May; 32(5):899-905. PubMed ID: 26836030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
    Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
    J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study].
    Maev IV; Okhlobystina OZ; Khalif IL; Andreev DN
    Ter Arkh; 2023 Feb; 95(1):38-51. PubMed ID: 37167114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain.
    Mira JJ; Lacima G; Cortés Gil X
    Rev Esp Enferm Dig; 2018 Oct; 110(10):612-620. PubMed ID: 30032636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).
    Taylor DCA; Abel JL; Martin C; Doshi JA; Essoi B; Korrer S; Reasner DS; Carson RT; Hunter AG
    J Med Econ; 2020 Oct; 23(10):1072-1083. PubMed ID: 32696684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland.
    Fisher M; Walker A; Falqués M; Moya M; Rance M; Taylor D; Lindner L
    Eur J Health Econ; 2016 Dec; 17(9):1091-1100. PubMed ID: 26728984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden.
    Fortea J; Prior M
    J Med Econ; 2013; 16(3):329-41. PubMed ID: 23216014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain.
    Nyrop KA; Palsson OS; Levy RL; Von Korff M; Feld AD; Turner MJ; Whitehead WE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):237-48. PubMed ID: 17593069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria.
    Hellström PM; Saito YA; Bytzer P; Tack J; Mueller-Lissner S; Chang L
    Am J Gastroenterol; 2011 Jul; 106(7):1299-307. PubMed ID: 21448146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.